AstraZeneca conducts fourth sale this week

The big pharma continues to shed non-core assets as it realigns its portfolio to focus on key areas. 

By Lisa LaMotta • Oct. 7, 2016

Pfizer continues trend of shedding non-core assets

The big pharma gets rid of more Hospira assets and gains a stake in pure-play infusion therapy company.

By Suzanne Elvidge • Oct. 7, 2016

Prescribed Reading: Pharma re-focuses, face-off at ESMO, Hep C boxed

Here's a closer look at the clinical trials, M&A, cool science and regulations that are driving the industry this week.

By Lisa LaMotta • Oct. 6, 2016

Catalent out-licenses ADC to Triphase

Triphase Accelerator of San Diego purchased rights to Catalent’s anti-body drug conjugate platform to make clinical headway against lymphoma.

By Joe Cantlupe • Oct. 6, 2016

Celltrion finds new partner after Pfizer exit

The partnership is the latest in a string of biosimilar marketing and production pacts that have popped up in the last few years.

By Jacob Bell • Oct. 6, 2016

BI sells to Elanco to complete Sanofi swap

Eli Lilly, which owns Elanco, will pay $885 million for the portfolio of cat and dog vaccines, adding to its growing animal health business. 

By Suzanne Elvidge • Oct. 6, 2016

OWC Pharma secures funding for cannabinoid drug

Interest in cannabidiol-based drugs has grown, particularly as GW Pharma continues to have success in late-stage clinical trials for Epidiolex. 

By Suzanne Elvidge • Oct. 5, 2016

AstraZeneca: Everything must go!

The British pharma announced its third out-licensing deal in as many days as it continues to shed non-core assets. 

By Lisa LaMotta • Oct. 5, 2016

Daiichi Sankyo links up with AgonOx in latest I/O deal

The Japanese drugmaker has built out its oncology pipeline, but suffered a setback when a Phase 3 lung cancer trial fell short of goal earlier this year. 

By Suzanne Elvidge • Oct. 5, 2016

Celgene CEO: myeloma and glioblastoma both priorities

Following a $600 million buy for Engmab, CEO Mark Alles said the company is expanding beyond multiple myeloma research toward brain cancer. 

By Joe Cantlupe • Oct. 4, 2016

AstraZeneca continues fire sale

The British pharma has been busy selling off non-core assets as part of an overall divestment and refocusing strategy. 

By Lisa LaMotta • Oct. 4, 2016

Amgen inks latest high price-tag research collaboration

With global oncology and neuroscience markets poised for growth, both Amgen and Nuevolution have been active on the deal-making front.

By Jacob Bell • Oct. 4, 2016

Sarepta steps up DMD dealmaking

Less than a week after signing a research deal with Catabasis Pharma, Sarepta paid $40 million upfront for rights to a DMD drug from Summit Therapeutics.

By Ned Pagliarulo • Oct. 4, 2016

AstraZeneca furthers sell-off strategy with new deal

The British pharma out-licensed rights to an inflammatory disease drug to Allergan, receiving $250 million upfront as it narrows its focus on key therapeutic areas. 

By Ned Pagliarulo • Oct. 3, 2016

UPDATED: BI plays hot potato with Hanmi, returns cancer drug

The German drugmaker abruptly abandoned a mid-stage lung cancer drug after reports surfaced about patient deaths. 

By Lisa LaMotta • Sept. 30, 2016

Bluebird flies into TCR deal with Medigene

Medigene will get $15 million upfront to develop TCR candidates, but a long chain of milestones could push total deal value much higher. 

By Suzanne Elvidge • Sept. 30, 2016

Catabasis hopes to ride Sarepta approval wave

Several weeks after winning approval for eteplirsen, the Cambridge-based company is teaming up with another biotech down the street to test a combo therapy in DMD.

By Lisa LaMotta • Sept. 29, 2016

Evotec inks deal with C4X Discovery

The drug discovery companies aim to collaboratively develop drugs targeting cancer and autoimmune diseases.

By Joe Cantlupe • Sept. 29, 2016

Oncodesign snaps up GSK French research center

The British pharma is shedding research facilities as it refocuses resources to key therapeutics areas. 

By Suzanne Elvidge • Sept. 29, 2016

Genentech commits $80M upfront in Hanmi licensing deal

The Roche subsidiary will have sole rights to commercialize Hanmi’s tumor-suppressing drug outside of South Korea.

By Jacob Bell • Sept. 29, 2016

As Repatha flounders, Amgen bolsters CV pipeline

With its PCSK9 inhibitor still flailing, the big biotech added two RNA interference drugs in a licensing deal with Arrowhead Pharmaceuticals. 

By Lisa LaMotta • Sept. 29, 2016

Small cancer biotech Tracon secures licensing pact with J&J

The deal gives Tracon $5M in equity and access to two preclinical oncology assets to bump up its early-stage pipeline.

By Suzanne Elvidge • Sept. 29, 2016

Athenex and SunGen seal deal for US market

The joint venture, which has the companies working together to launch and market seven drugs, is one of several it has planned for the near term.

By Joe Cantlupe • Sept. 28, 2016

Suitors circle as Bayer considers asset sale: report

Mylan and Lupin are among a number of drugmakers reportedly lining up to buy Bayer's dermatology business, according to Bloomberg.   

By Joe Cantlupe • Sept. 28, 2016

Shire pulls out of biosimilar development

Two Phase 3 biosimilars were returned to development partners as Shire reevaluates Baxalta assets to focus further on rare diseases. 

By Suzanne Elvidge • Sept. 28, 2016